Kasturi Wilson to succeed Steven Enderby as Hemas Group Chief Executive Officer

• Enderby to continue as a member on boards of Hemas’ hotel ventures

Hemas Holdings PLC yesterday announced the appointment of Kasturi Chellaraja Wilson as Group Chief Executive Officer, effective October 1, 2020, succeeding 
Steven Enderby.

As part of a planned succession, Kasturi will take on the role of Deputy CEO and be appointed to the Hemas Holdings PLC board, effective July 1, 2020.

“The board decided to appoint Kasturi as Group CEO following a thorough selection process in line with our company’s succession plans, which prioritise developing internal talent,” Hemas Holdings Chairman Husein Esufally said. “Kasturi is no stranger to Hemas, having been with us since 2002, and we are delighted that a long-standing colleague has risen to occupy the highest executive position in the group,” he added.

Commenting on the transition Esufally said Steven’s leadership over the last six years had enabled Hemas to become a more streamlined, purposeful and effective organisation.

“The board joins me in thanking Steven for his immense contribution to Hemas over the years. Further, we are happy that Steven will continue to be associated with us as a member on the boards of our hotel ventures,” he said.

“The future presents many exciting opportunities in Sri Lanka and in the Asian region, not only to scale our existing businesses, but also to expand into ‘new growth’ areas of consumer, healthcare and mobility, which constitute our core verticals. Hemas’ revenues have doubled over the last five years, and we are certainly looking for a faster pace of growth in the years ahead,” added Esufally.

In a career spanning two decades at Hemas, Kasturi rose through the ranks to become the Chief Process Officer and thereafter in 2011 she took on the leadership of the aviation, travel and mobility businesses of the group. 
In 2016, Kasturi was tasked with leading Hemas Pharmaceuticals, where she worked closely with all stakeholders to satisfy emerging patient needs whilst delivering sustainable growth in a challenging regulatory environment. 

Kasturi is a Fellow of the Chartered Institute of Management Accountants, UK. She has attended many leadership programmes over the span of her career, most notably the Senior Executive Leadership Programme at Harvard Business School. 

Over the years, she has actively contributed to industry forums and committees. She serves as a board member of Capital Alliance Ltd and is the President of the Sri Lanka Chamber of Pharmaceutical Industry. 

Kasturi was also recognised by the Parliament of Sri Lanka in 2019 and awarded a position on its list of Women Changemakers.

Headquartered in Sri Lanka, Hemas also has operations in Bangladesh, West Bengal and Myanmar.